{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:17:22Z","timestamp":1788585442326,"version":"build-2803163510"},"reference-count":39,"publisher":"The Society for Free Radical Research Japan","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Biochem. Nutr."],"published-print":{"date-parts":[[2026,9,1]]},"DOI":"10.3164\/jcbn.26-55","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T22:10:22Z","timestamp":1780611022000},"page":"150-157","source":"Crossref","is-referenced-by-count":0,"title":["Combined inhibition of MEK and FOXO1 synergistically suppresses MDA-MB-231 cell proliferation with reduced LOXL4"],"prefix":"10.3164","volume":"79","author":[{"given":"Tetsuro","family":"Kamiya","sequence":"first","affiliation":[{"name":"Laboratory of Clinical Pharmaceutics, Gifu Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asumi","family":"Kanaya","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmaceutics, Gifu Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Otsuka","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmaceutics, Gifu Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Hara","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Pharmaceutics, Gifu Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1739","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Perou CM, S\u00f8rlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747\u2013752.","DOI":"10.1038\/35021093"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010; 363: 1938\u20131948.","DOI":"10.1056\/NEJMra1001389"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429\u20134434.","DOI":"10.1158\/1078-0432.CCR-06-3045"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov 2019; 9: 176\u2013198.","DOI":"10.1158\/2159-8290.CD-18-1177"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Park M, Kim D, Ko S, Kim A, Mo K, Yoon H. Breast cancer metastasis: mechanisms and therapeutic implications. Int J Mol Sci 2022; 23: 6806.","DOI":"10.3390\/ijms23126806"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Kim JH, Kim MK, Lee HE, et al. Constitutive phosphorylation of the FOXO1A transcription factor as a prognostic variable in gastric cancer. Mod Pathol 2007; 20: 835\u2013842.","DOI":"10.1038\/modpathol.3800789"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Tomiyasu H, Habara M, Hanaki S, Sato Y, Miki Y, Shimada M. FOXO1 promotes cancer cell growth through MDM2-mediated p53 degradation. J Biol Chem 2024; 300: 107209.","DOI":"10.1016\/j.jbc.2024.107209"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Kamiya T, Yamaguchi Y, Oka M, Hara H. Combined action of FOXO1 and superoxide dismutase 3 promotes MDA-MB-231 cell migration. Free Radic Res 2022; 56: 106\u2013114.","DOI":"10.1080\/10715762.2022.2049770"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Baker AM, Bird D, Lang G, Cox TR, Erler JT. Lysyl oxidase enzymatic function increases stiffness to drive colorectal cancer progression through FAK. Oncogene 2013; 32: 1863\u20131868.","DOI":"10.1038\/onc.2012.202"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Laczko R, Szauter KM, Jansen MK, et al. Active lysyl oxidase (LOX) correlates with focal adhesion kinase (FAK)\/paxillin activation and migration in invasive astrocytes. Neuropathol Appl Neurobiol 2007; 33: 631\u2013643.","DOI":"10.1111\/j.1365-2990.2007.00858.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Xiao Q, Ge G. Lysyl oxidase, extracellular matrix remodeling and cancer metastasis. Cancer Microenviron 2012; 5: 261\u2013273.","DOI":"10.1007\/s12307-012-0105-z"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Wang TH, Hsia SM, Shieh TM. Lysyl oxidase and the tumor microenvironment. Int J Mol Sci 2016; 18: 62.","DOI":"10.3390\/ijms18010062"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Choi SK, Kim HS, Jin T, Moon WK. LOXL4 knockdown enhances tumor growth and lung metastasis through collagen-dependent extracellular matrix changes in triple-negative breast cancer. Oncotarget 2017; 8: 11977\u201311989.","DOI":"10.18632\/oncotarget.14450"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Kamiya T, Ishii K, Ozawa K, Hara H. Bortezomib suppresses TGF-\u03b21-mediated LOXL4 reduction through the inhibition of MEK\/ERK pathways in MDA-MB-231 cells. J Recept Signal Transduct Res 2025; 45: 73\u201382.","DOI":"10.1080\/10799893.2025.2455594"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Kamiya T, Teruya R, Tahara H, et al. Copper induces cystine\/glutamate antiporter SLC7A11 through the activation of Nrf2 and Atox1 pathways. Free Radic Res 2025; 59: 634\u2013645.","DOI":"10.1080\/10715762.2025.2560847"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Do HTT, Cho J. Involvement of the ERK\/HIF-1\u03b1\/EMT pathway in XCL1-induced migration of MDA-MB-231 and SK-BR-3 breast cancer cells. Int J Mol Sci 2020; 22: 89.","DOI":"10.3390\/ijms22010089"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Greene AG, Eivers SB, Dervan EWJ, O'Brien CJ, Wallace DM. Lysyl oxidase like 1: biological roles and regulation. Exp Eye Res 2020; 193: 107975.","DOI":"10.1016\/j.exer.2020.107975"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Flores D, Lopez A, Udawant S, Gunn B, Keniry M. The FOXO1 inhibitor AS1842856 triggers apoptosis in glioblastoma multiforme and basal-like breast cancer cells. FEBS Open Bio 2023; 13: 352\u2013362.","DOI":"10.1002\/2211-5463.13547"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Chen X, Shao Y, Wei W, et al. Downregulation of LOX promotes castration-resistant prostate cancer progression via IGFBP3. J Cancer 2021; 12: 7349\u20137357.","DOI":"10.7150\/jca.61131"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Wu J, Li J, Xu H, Qiu N, Huang X, Li H. Periostin drives extracellular matrix degradation, stemness, and chemoresistance by activating the MAPK\/ERK signaling pathway in triple-negative breast cancer cells. Lipids Health Dis 2023; 22: 153.","DOI":"10.1186\/s12944-023-01912-1"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Boufraqech M, Patel D, Nilubol N, et al. Lysyl oxidase is a key player in BRAF\/MAPK pathway-driven thyroid cancer aggressiveness. Thyroid 2019; 29: 79\u201392.","DOI":"10.1089\/thy.2018.0424"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Guadall A, Orriols M, Alcudia JF, Cachofeiro V, Martinez-Gonzalez J, Rodriguez C. Hypoxia-induced ROS signaling is required for LOX up-regulation in endothelial cells. Front Biosci (Elite Ed) 2011; 3: 955\u2013967.","DOI":"10.2741\/e301"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Hameedaldeen A, Liu J, Batres A, Graves GS, Graves DT. FOXO1, TGF-\u03b2 regulation and wound healing. Int J Mol Sci 2014; 15: 16257\u201316269.","DOI":"10.3390\/ijms150916257"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Li J, Guo Y, Duan L, et al. AKR1B10 promotes breast cancer cell migration and invasion via activation of ERK signaling. Oncotarget 2017; 8: 33694\u201333703.","DOI":"10.18632\/oncotarget.16624"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Qin WY, Feng SC, Sun YQ, Jiang GQ. MiR-96-5p promotes breast cancer migration by activating MEK\/ERK signaling. J Gene Med 2020; 22: e3188.","DOI":"10.1002\/jgm.3188"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646\u2013674.","DOI":"10.1016\/j.cell.2011.02.013"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011; 147: 275\u2013292.","DOI":"10.1016\/j.cell.2011.09.024"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Chinipardaz Z, Yuan G, Liu M, Graves DT, Yang S. Diabetes impairs fracture healing through Foxo1 mediated disruption of ciliogenesis. Cell Death Discov 2023; 9: 299.","DOI":"10.1038\/s41420-023-01562-3"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Wang Y, Lyu Z, Qin Y, et al. FOXO1 promotes tumor progression by increased M2 macrophage infiltration in esophageal squamous cell carcinoma. Theranostics 2020; 10: 11535\u201311548.","DOI":"10.7150\/thno.45261"},{"key":"30","unstructured":"30 Jeon HH, Yu Q, Witek L, et al. Clinical application of a FOXO1 inhibitor improves connective tissue healing in a diabetic minipig model. Am J Transl Res 2021; 13: 781\u2013791."},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Takemoto R, Kamiya T, Hara H, Adachi T. Lysyl oxidase expression is regulated by the H3K27 demethylase Jmjd3 in tumor-associated M2-like macrophages. J Clin Biochem Nutr 2020; 66: 110\u2013115.","DOI":"10.3164\/jcbn.19-67"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Lee S, Rauch J, Kolch W. Targeting MAPK signaling in cancer: mechanisms of drug resistance and sensitivity. Int J Mol Sci 2020; 21: 1102.","DOI":"10.3390\/ijms21031102"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets 2012; 16: 103\u2013119.","DOI":"10.1517\/14728222.2011.645805"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Romero-Becerra R, Santamans AM, Folgueira C, Sabio G. p38 MAPK pathway in the heart: new insights in health and disease. Int J Mol Sci 2020; 21: 7412.","DOI":"10.3390\/ijms21197412"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Psychogios N, Hau DD, Peng J, et al. The human serum metabolome. PLoS One 2011; 6: e16957.","DOI":"10.1371\/journal.pone.0016957"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Sato H, Shiiya A, Kimata M, et al. Redox imbalance in cystine\/glutamate transporter-deficient mice. J Biol Chem 2005; 280: 37423\u201337429.","DOI":"10.1074\/jbc.M506439200"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Caunt CJ, Sale MJ, Smith PD, Cook SJ. MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nat Rev Cancer 2015; 15: 577\u2013592.","DOI":"10.1038\/nrc4000"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Subbiah V, Baik C, Kirkwood JM. Clinical development of BRAF plus MEK inhibitor combinations. Trends Cancer 2020; 6: 797\u2013810.","DOI":"10.1016\/j.trecan.2020.05.009"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Schreck KC, Allen AN, Wang J, Pratilas CA. Combination MEK and mTOR inhibitor therapy is active in models of glioblastoma. Neurooncol Adv 2020; 2: vdaa138.","DOI":"10.1093\/noajnl\/vdaa138"}],"container-title":["Journal of Clinical Biochemistry and Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jcbn\/79\/2\/79_26-55\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:50:36Z","timestamp":1788583836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jcbn\/79\/2\/79_26-55\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.3164\/jcbn.26-55","relation":{},"ISSN":["0912-0009","1880-5086"],"issn-type":[{"value":"0912-0009","type":"print"},{"value":"1880-5086","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"26-55"}}